655 related articles for article (PubMed ID: 21345145)
1. Rational therapeutic combinations with histone deacetylase inhibitors for the treatment of cancer.
Thurn KT; Thomas S; Moore A; Munster PN
Future Oncol; 2011 Feb; 7(2):263-83. PubMed ID: 21345145
[TBL] [Abstract][Full Text] [Related]
2. HDAC Inhibitors.
Olzscha H; Bekheet ME; Sheikh S; La Thangue NB
Methods Mol Biol; 2016; 1436():281-303. PubMed ID: 27246222
[TBL] [Abstract][Full Text] [Related]
3. HDAC inhibitor-based therapies: can we interpret the code?
New M; Olzscha H; La Thangue NB
Mol Oncol; 2012 Dec; 6(6):637-56. PubMed ID: 23141799
[TBL] [Abstract][Full Text] [Related]
4. Histone Deacetylase Inhibitors as Anticancer Drugs.
Eckschlager T; Plch J; Stiborova M; Hrabeta J
Int J Mol Sci; 2017 Jul; 18(7):. PubMed ID: 28671573
[TBL] [Abstract][Full Text] [Related]
5. Targeting histone deacetylases: development of vorinostat for the treatment of cancer.
Richon VM
Epigenomics; 2010 Jun; 2(3):457-65. PubMed ID: 22121904
[TBL] [Abstract][Full Text] [Related]
6. Class I HDACs Affect DNA Replication, Repair, and Chromatin Structure: Implications for Cancer Therapy.
Stengel KR; Hiebert SW
Antioxid Redox Signal; 2015 Jul; 23(1):51-65. PubMed ID: 24730655
[TBL] [Abstract][Full Text] [Related]
7. The safety profile of vorinostat (suberoylanilide hydroxamic acid) in hematologic malignancies: A review of clinical studies.
Duvic M; Dimopoulos M
Cancer Treat Rev; 2016 Feb; 43():58-66. PubMed ID: 26827693
[TBL] [Abstract][Full Text] [Related]
8. HDAC inhibitors in cancer biology: emerging mechanisms and clinical applications.
Khan O; La Thangue NB
Immunol Cell Biol; 2012 Jan; 90(1):85-94. PubMed ID: 22124371
[TBL] [Abstract][Full Text] [Related]
9. Natural Product Inhibitors of Histone Deacetylases as New Anticancer Agents.
Hanikoglu A; Hanikoglu F; Ozben T
Curr Protein Pept Sci; 2018; 19(3):333-340. PubMed ID: 28059044
[TBL] [Abstract][Full Text] [Related]
10. Targeted cancer therapy: giving histone deacetylase inhibitors all they need to succeed.
Gryder BE; Sodji QH; Oyelere AK
Future Med Chem; 2012 Mar; 4(4):505-24. PubMed ID: 22416777
[TBL] [Abstract][Full Text] [Related]
11. Histone deacetylase inhibitors in clinical studies as templates for new anticancer agents.
Mottamal M; Zheng S; Huang TL; Wang G
Molecules; 2015 Mar; 20(3):3898-941. PubMed ID: 25738536
[TBL] [Abstract][Full Text] [Related]
12. Histone deacetylase inhibitors in hematological malignancies and solid tumors.
Chun P
Arch Pharm Res; 2015 Jun; 38(6):933-49. PubMed ID: 25653088
[TBL] [Abstract][Full Text] [Related]
13. New and emerging HDAC inhibitors for cancer treatment.
West AC; Johnstone RW
J Clin Invest; 2014 Jan; 124(1):30-9. PubMed ID: 24382387
[TBL] [Abstract][Full Text] [Related]
14. Histone deacetylase inhibitors in cancer therapy.
Lane AA; Chabner BA
J Clin Oncol; 2009 Nov; 27(32):5459-68. PubMed ID: 19826124
[TBL] [Abstract][Full Text] [Related]
15. Targeting Histone Deacetylases with Natural and Synthetic Agents: An Emerging Anticancer Strategy.
Singh AK; Bishayee A; Pandey AK
Nutrients; 2018 Jun; 10(6):. PubMed ID: 29882797
[TBL] [Abstract][Full Text] [Related]
16. Epigenetic therapy of cancer with histone deacetylase inhibitors.
Lakshmaiah KC; Jacob LA; Aparna S; Lokanatha D; Saldanha SC
J Cancer Res Ther; 2014; 10(3):469-78. PubMed ID: 25313724
[TBL] [Abstract][Full Text] [Related]
17. Role of histone deacetylases and their inhibitors in cancer biology and treatment.
Beumer JH; Tawbi H
Curr Clin Pharmacol; 2010 Aug; 5(3):196-208. PubMed ID: 20406169
[TBL] [Abstract][Full Text] [Related]
18. HDAC inhibitors for the treatment of cutaneous T-cell lymphomas.
Rangwala S; Zhang C; Duvic M
Future Med Chem; 2012 Mar; 4(4):471-86. PubMed ID: 22416775
[TBL] [Abstract][Full Text] [Related]
19. Histone deacetylase inhibitors: molecular and biological activity as a premise to clinical application.
Santini V; Gozzini A; Ferrari G
Curr Drug Metab; 2007 May; 8(4):383-93. PubMed ID: 17504226
[TBL] [Abstract][Full Text] [Related]
20. A novel small molecule hybrid of vorinostat and DACA displays anticancer activity against human hormone-refractory metastatic prostate cancer through dual inhibition of histone deacetylase and topoisomerase I.
Yu CC; Pan SL; Chao SW; Liu SP; Hsu JL; Yang YC; Li TK; Huang WJ; Guh JH
Biochem Pharmacol; 2014 Aug; 90(3):320-30. PubMed ID: 24915421
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
